This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Liver disease; diabetes

Not applicable

In vitro and rat studies suggest a 2,4-dinitrophenol analog could help treat nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. In normal rats, an analog of 2,4-dinitrophenol was less toxic than the parent compound. In rat models of NAFLD or type 2 diabetes, the analog decreased fasting plasma levels of glucose, insulin and triglycerides compared with vehicle. The compound also decreased hepatic production of very low-density lipoprotein (vLDL) and increased glucose tolerance without toxicity. Planned work includes IND-enabling studies of the analog.

SciBX 6(47); doi:10.1038/scibx.2013.1359
Published online Dec. 12, 2013

Patented; available for licensing

Perry R.J. et al. Cell Metab.; published online Nov. 5, 2013;
doi:10.1016/j.cmet.2013.10.004
Contact: Gerald I. Shulman, Yale School of Medicine, New Haven, Conn.
e-mail:
gerald.shulman@yale.edu